Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabolism Research

Executive Summary: Acifran (SKU B6848) is a high-purity, (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, acting as a selective agonist for HM74A/GPR109A and GPR109B hydroxycarboxylic acid receptors, crucial in lipid metabolism regulation (APExBIO). Recent cryo-EM studies provide direct structural evidence of Acifran binding to both HCAR3 and HCAR2, elucidating the molecular basis for its selectivity (Ye et al., 2025). The compound is supplied at ≥98% purity, with a molecular weight of 218.21 and confirmed solubility characteristics (APExBIO). Acifran is a key benchmark tool for dissecting lipid signaling pathways in metabolic disorder research (INCB article). Proper storage and handling are essential to preserve biological activity.

Biological Rationale

Lipid metabolism is central to energy homeostasis and metabolic disease pathogenesis. Hydroxycarboxylic acid receptors (HCARs), specifically HM74A/GPR109A (HCAR2) and GPR109B (HCAR3), are G-protein coupled receptors involved in sensing metabolic intermediates and regulating lipolysis (Ye et al., 2025). Dysregulation of these pathways contributes to disorders such as dyslipidemia, obesity, and type 2 diabetes. Selective agonists like Acifran enable precise modulation of these receptors, facilitating the study of lipid signaling and the development of novel therapeutics (VSV-G Peptide article). Acifran’s receptor selectivity minimizes off-target effects, making it a valuable research compound for metabolic disorder models.

Mechanism of Action of Acifran

Acifran directly binds to HM74A/GPR109A and GPR109B, stabilizing their active conformations. This binding initiates Gi protein coupling, leading to decreased intracellular cAMP levels and suppression of lipolysis in adipocytes (Ye et al., 2025). Cryo-EM structures (PDB: 9JKX, 9JKY) show Acifran occupying the orthosteric pocket, engaging in π–π interactions with F1073.32 in HCAR3 and L1073.32 in HCAR2. These molecular contacts dictate selectivity and functional outcomes. The compound’s hypolipidemic effect is mediated by downstream inhibition of hormone-sensitive lipase activity. Unlike some HCAR2 agonists, Acifran’s activation of HCAR3 is not associated with flushing, offering a differentiated pharmacological profile (PrecisionFDA article—this article provides a translational roadmap, whereas the current piece details atomic mechanism).

Evidence & Benchmarks

• Acifran forms a stable complex with HCAR3-Gi1-scFv16, with a cryo-EM resolution of 3.18 Å (Ye et al., 2025, DOI).
• Acifran also binds HCAR2-Gi1, resolved at 2.72 Å, confirming dual receptor selectivity (Ye et al., 2025, DOI).
• Key amino acid residues (e.g., F1073.32, V832.60) mediate Acifran selectivity through π–π interactions and pocket volume differences (Ye et al., 2025, DOI).
• Biochemical assays (cAMP inhibition in HEK-293 cells) validate functional agonist activity (Ye et al., 2025, DOI).
• APExBIO supplies Acifran (B6848) at ≥98.00% purity; solubility is <21.82 mg/ml in ethanol and DMSO (APExBIO).
• Acifran is validated as a benchmark for lipid signaling pathway modulation in metabolic disorder research (INCB article—the current article provides updated structural context).

Applications, Limits & Misconceptions

Acifran is primarily used in preclinical research to probe lipid metabolism and GPCR signaling. It enables dissection of signaling cascades downstream of HCAR2/3 in cellular and animal models (VSV-G Peptide article). Its selectivity profile allows researchers to distinguish receptor-specific effects.

Common Pitfalls or Misconceptions

• Not for diagnostic or clinical use: Acifran is strictly for research; it is not approved for therapeutic applications (APExBIO).
• Long-term solution storage leads to loss of activity: Prepared solutions should be used promptly to preserve potency.
• Not effective in models lacking HM74A/GPR109A or GPR109B expression: Off-target effects are minimal, but efficacy depends on target receptor presence.
• Does not mimic all endogenous ligand effects: Acifran’s selectivity may not recapitulate the full spectrum of physiological responses.
• Solubility limitations: Exceeding recommended concentrations in ethanol or DMSO can result in precipitation.

Workflow Integration & Parameters

To ensure reproducible results, Acifran should be stored at -20°C and shipped with blue ice to maintain stability (APExBIO). Dissolution should be performed in ethanol or DMSO at concentrations below 21.82 mg/ml. For cell-based assays, Acifran is typically used at 0.1–10 μM, depending on receptor expression and experimental endpoints. Solutions are not recommended for long-term storage; freshly prepare immediately prior to use. Researchers should confirm target receptor expression in their model systems. Controls using vehicle and/or alternative agonists are recommended to validate specificity. Refer to this scenario-driven guide for Q&A on experimental design with Acifran, which this article extends by providing atomic-level structural rationale.

Conclusion & Outlook

Acifran (B6848) from APExBIO represents a chemically defined, structurally validated HM74A/GPR109A and GPR109B agonist for advanced lipid metabolism research. Its molecular interaction profile, confirmed by cryo-EM, sets a new standard for mechanistic studies of lipid signaling and metabolic disorder pathways (Ye et al., 2025). As the structural and functional data landscape expands, Acifran will continue to play a central role in preclinical research, supporting the rational design of next-generation metabolic disease therapeutics.

For further details, visit the official product page or see the latest mechanistic review—this article adds atomic-level evidence to the workflow-focused discussion.